DTaP-Hib vaccine

DTaP-Hib vaccine
Combination of
Intramuscular injection
ATC code	J07AG52 (WHO) ;
Identifiers
CAS Number	1670254-07-5;

DTaP-Hib vaccine is a

Haemophilus influenzae type B.^{[citation needed}

]

A branded formulation was marketed in the US as

Daptacel.^{[citation needed}

]

References

^ "Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions". Drugs.com. Retrieved 15 July 2018.
^ "Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine". Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 15 November 1996. pp. 993–995. Retrieved 15 July 2018.
US Food and Drug Administration. Archived from the original
(PDF) on 12 January 2017. Retrieved 15 July 2018.

US Food and Drug Administration
. Retrieved 15 July 2018.
^ "Selected Discontinued U.S. Vaccines" (PDF). Centers for Disease Control and Prevention. Retrieved 15 July 2018.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=DTaP-Hib_vaccine&oldid=1183561052"

[1] "Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions". Drugs.com. Retrieved 15 July 2018.

[2] "Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine". Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 15 November 1996. pp. 993–995. Retrieved 15 July 2018.

[3] US Food and Drug Administration. Archived from the original
(PDF) on 12 January 2017. Retrieved 15 July 2018.

[4] US Food and Drug Administration
. Retrieved 15 July 2018.

[5] "Selected Discontinued U.S. Vaccines" (PDF). Centers for Disease Control and Prevention. Retrieved 15 July 2018.